|
TAB2 expression based on
|
| Comparison | Statistical significance |
| Normal-vs-Primary | 2.30830000003124E-06 |
|
Note
Cancer stage information is not available for 2 samples.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Stage1 |
7.81200000000704E-05 |
| Normal-vs-Stage2 |
3.476600E-03 |
| Normal-vs-Stage3 |
1.22489999998532E-06 |
| Normal-vs-Stage4 |
1.72080000004904E-06 |
| Stage1-vs-Stage2 |
9.646400E-01 |
| Stage1-vs-Stage3 |
1.057030E-01 |
| Stage1-vs-Stage4 |
1.014150E-01 |
| Stage2-vs-Stage3 |
2.651800E-01 |
| Stage2-vs-Stage4 |
1.848840E-01 |
| Stage3-vs-Stage4 |
7.081600E-01 |
|
|
Note
Patient race information is not available for 92 samples and one samples from American Indians not included in the above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Caucasian |
9.64479999976398E-07 |
| Normal-vs-AfricanAmerican |
2.123600E-01 |
| Normal-vs-Asian |
5.62640000000281E-05 |
| Caucasian-vs-AfricanAmerican |
5.110200E-02 |
| Caucasian-vs-Asian |
7.591400E-01 |
| AfricanAmerican-vs-Asian |
4.834400E-02 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Male |
2.98330000036984E-07 |
| Normal-vs-Female |
3.94900000000309E-05 |
| Male-vs-Female |
1.108220E-01 |
|
|
Note
Seventeen samples from patient below 21 years not considered in above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Age(21-40Yrs) |
1.556960E-04 |
| Normal-vs-Age(41-60Yrs) |
1.87767999999533E-05 |
| Normal-vs-Age(61-80Yrs) |
4.11420000000495E-05 |
| Normal-vs-Age(81-100Yrs) |
3.519600E-03 |
| Age(21-40Yrs)-vs-Age(41-60Yrs) |
4.843600E-01 |
| Age(21-40Yrs)-vs-Age(61-80Yrs) |
5.117000E-01 |
| Age(21-40Yrs)-vs-Age(81-100Yrs) |
2.378800E-01 |
| Age(41-60Yrs)-vs-Age(61-80Yrs) |
9.499400E-01 |
| Age(41-60Yrs)-vs-Age(81-100Yrs) |
3.405200E-01 |
| Age(61-80Yrs)-vs-Age(81-100Yrs) |
3.386400E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Classical-VS-Tall |
4.209700E-02 |
| Classical-VS-Follicular |
7.721600E-01 |
| Classical-VS-Other |
2.625400E-01 |
| Classical-VS-Normal |
5.67759999999806E-05 |
| Tall-VS-Follicular |
8.027800E-02 |
| Tall-VS-Other |
9.265600E-01 |
| Tall-VS-Normal |
1.53858999999423E-05 |
| Follicular-VS-Other |
4.147400E-01 |
| Follicular-VS-Normal |
1.298690E-03 |
| Other-VS-Normal |
1.180410E-02 |
|
|
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 50 samples.
| pathologic_N descriptions |
| N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
| N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-N0 |
3.50860000000175E-05 |
| Normal-vs-N1 |
3.11800000041274E-07 |
| N0-vs-N1 |
5.085500E-02 |
|
|
